Who is sponsoring NCT04150016?

NCT04150016 is sponsored by Xijing Hospital.

What drugs are being tested in NCT04150016?

Interventions in NCT04150016: percutaneous coronary intervention.

What condition does NCT04150016 study?

NCT04150016 studies Drug-eluting Stents, Percutaneous Coronary Intervention, Optical Coherence Tomography, ST-Elevation Myocardial Infarction.

Is NCT04150016 still recruiting?

NCT04150016 is currently status unknown. Last updated 4 November 2019.

Last reviewed 2019-11-04 · How we verify

NCT04150016

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

In-stent Repair and Vessel Reaction of STEMI Patients With OCT

Status unknown NA Last updated 4 November 2019

What this trial tests

NA trial testing percutaneous coronary intervention in Drug-eluting Stents in 44 participants. Status unknown.

Timeline

8 March 2019

Primary endpoint
1 December 2020

1 December 2021

Quick facts

Lead sponsor	Xijing Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	8 March 2019
Primary completion	1 December 2020
Estimated completion	1 December 2021
Sites	1 location across China

Drugs / interventions tested

percutaneous coronary intervention

Conditions studied

Drug-eluting Stents — all drugs for Drug-eluting Stents →
Percutaneous Coronary Intervention — all drugs for Percutaneous Coronary Intervention →
Optical Coherence Tomography — all drugs for Optical Coherence Tomography →
ST-Elevation Myocardial Infarction — all drugs for ST-Elevation Myocardial Infarction →

Sponsor

Xijing Hospital

Who can join

Adults 18 to 75, any sex, with Drug-eluting Stents or Percutaneous Coronary Intervention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multi-center, non-inferior, randomized controlled clinical trial, aims to use optical Coherence tomography to observe the the early- and mid-stage vessel repair and neointimal proliferation. And to assess the safety and effectiveness of the Firehawk™ sirolimus target-eluting coronary stent system with abluminal grooves containing a biodegradable polymer (Firehawk™) comparing the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ST-elevation myocardial infarction (STEMI).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A Randomized Comparison of the Healing Response Between the Firehawk Stent and the Xience Stent in Patients With ST-Segment Elevation Myocardial Infarction at 6 Months of Follow-Up (TARGET STEMI OCT China Trial): An Optical Coherence Tomography Study.
He Y, Wang R, Liu J, Li F, et al · · 2022 · cited 8× · PMID 35722108 · DOI 10.3389/fcvm.2022.895167
Piezo1 Upregulation in Monocyte-Derived Macrophages Impairs Post-Myocardial Infarction Cardiac Repair via Defective Efferocytosis and Enhanced Ferroptosis.
Peng L, Xia Y, Zhao H, Guo Y, et al · · 2026 · cited 4× · PMID 41214880 · DOI 10.1002/advs.202510991

Verify or expand the search:

Other trials of percutaneous coronary intervention

Trials testing the same drug.

NCT07444346 — Intravascular Imaging-Guided Intravascular Lithotripsy for Severe Coronary Calcified Lesions. · not yet recruiting
NCT07297641 — Intravascular Imaging-Guided Versus Angiography- Guided PCI in Patients With DES-ISR · recruiting
NCT07312318 — AI-Driven Dynamic Prediction of Non-Target Lesion Progression After PCI: A Chinese Multicenter Cohort Study · recruiting
NCT06853470 — Prospective Evaluation for Receiving SynFlow 3.0 Interventional Circulatory Support in High-risk PCI: A Randomized Contr · NA · completed
NCT05883579 — Application of Coronary Artery Chronic Total Occlusion Scoring Systems · unknown

Other Xijing Hospital trials

Trials by the same sponsor.

NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04150016 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
Last refreshed: 4 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04150016.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing